← Back to all trials
Active Not Recruiting
NCT02123758
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Sex: Male
Ages: 18 Years – 99 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 57
Sponsor: Aragon Pharmaceuticals, Inc.
Location: Los Angeles California
Summary
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.
Eligibility Criteria
Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (\
Source: ClinicalTrials.gov (NCT02123758). StuddyBuddy aggregates publicly available trial information.
